IMMUNOVANT INC's ticker is IMVT and the CUSIP is 45258J102. A total of 121 filers reported holding IMMUNOVANT INC in Q4 2021. The put-call ratio across all filers is 0.09 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $60,433,307 | +692.1% | 310,558 | -22.8% | 7.27% | +498.3% |
| Q2 2023 | $7,629,734 | -47.4% | 402,200 | -57.0% | 1.22% | -63.1% |
| Q1 2023 | $14,497,166 | -17.7% | 934,698 | -5.9% | 3.29% | -22.6% |
| Q4 2022 | $17,623,975 | +289.1% | 992,900 | +22.3% | 4.25% | +371.4% |
| Q3 2022 | $4,529,000 | +527.3% | 811,700 | +877.4% | 0.90% | +1668.6% |
| Q3 2021 | $722,000 | -89.4% | 83,046 | -87.1% | 0.05% | -90.7% |
| Q2 2021 | $6,800,000 | -29.9% | 643,200 | +6.4% | 0.55% | +68.7% |
| Q1 2021 | $9,697,000 | -10.9% | 604,500 | +156.6% | 0.33% | -32.1% |
| Q4 2020 | $10,882,000 | -3.9% | 235,587 | -26.8% | 0.48% | -41.5% |
| Q3 2020 | $11,328,000 | +64.9% | 321,887 | +14.1% | 0.82% | +49.9% |
| Q2 2020 | $6,871,000 | -47.6% | 282,163 | -66.5% | 0.55% | -44.5% |
| Q1 2020 | $13,113,000 | +63.9% | 842,463 | +67.1% | 0.99% | -23.9% |
| Q4 2019 | $8,000,000 | – | 504,117 | – | 1.30% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Alpine Global Management, LLC | 4,448,017 | $17,347,000 | 4.39% |
| Deep Track Capital, LP | 9,455,000 | $36,875,000 | 2.42% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 233 | $60,000,000 | 0.63% |
| Octagon Capital Advisors LP | 579,061 | $2,258,000 | 0.60% |
| Eventide Asset Management | 5,372,512 | $20,953,000 | 0.45% |
| WITTENBERG INVESTMENT MANAGEMENT, INC. | 174,000 | $679,000 | 0.29% |
| Frazier Life Sciences Management, L.P. | 585,759 | $2,284,000 | 0.22% |
| BCK CAPITAL MANAGEMENT LP | 54,293 | $212,000 | 0.16% |
| PLATINUM INVESTMENT MANAGEMENT LTD | 777,590 | $3,033,000 | 0.12% |
| Bridgefront Capital, LLC | 15,649 | $61,000 | 0.07% |